Adial Pharmaceuticals Secures $32M PIPE Financing and Expands Leadership Team
Event summary
- Adial Pharmaceuticals closed $32M of a $64M PIPE financing on June 12, 2026, including conversion of outstanding notes from the Azora acquisition.
- The company granted restricted stock units and stock options to new executives Matthew Davidson (Chief Development Officer) and Julie Saiki (EVP of Strategy).
- The financing was led by Coastlands Capital, with participation from several biotech specialists and institutional investors.
- Proceeds will advance the lead colon-targeted AhR program (AT177) through key clinical milestones.
The big picture
Adial Pharmaceuticals' $32M PIPE financing and strategic leadership hires underscore its pivot from addiction treatments to ulcerative colitis, following the Azora acquisition. The move aligns with broader industry trends of biotech companies seeking specialized therapies with high market potential. The participation of notable investors like Coastlands Capital and Kern Capital signals confidence in Adial's ability to execute its clinical strategy and deliver value to shareholders.
What we're watching
- Clinical Milestones
- How the $32M financing will accelerate the development of AT177 through key clinical milestones.
- Leadership Impact
- Whether new executives Matthew Davidson and Julie Saiki can drive strategic growth and operational efficiency.
- Market Positioning
- The pace at which Adial can establish AT177 as a market leader in ulcerative colitis treatment.